2023-506509-21-00CompletedPhase 1
A Phase 1b, Open-Label, Multiple Ascending Dose, Multicenter Study of VRG50635 in Participants With Sporadic and Familial Amyotrophic Lateral Sclerosis Followed by Long-Term Treatment
Source: EU CTIS (euclinicaltrials.eu) · Last updated 14 Jul 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (actual)
- First submitted
- 15 Sept 2023
- Start date
- 8 Mar 2024
- Lead sponsor
- Verge Genomics
- Diseases
- ALS (motor neurone disease)
- EU CT number
- 2023-506509-21-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 47
- 9 sites in 5 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (9)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UZ Leuven | Leuven | Belgium | Completed |
| Bellvitge University Hospital | L'hospitalet De Llobregat | Spain | Completed |
| Hospital Universitario Regional de Málaga | Málaga | Spain | Completed |
| Meilahti Hospital | Helsinki | Finland | Completed |
| University Of Eastern Finland | Kuopio | Finland | Completed |
| Tampere University Hospital | Tampere | Finland | Completed |
| Turku University Hospital | Turku | Finland | Completed |
| Universitair Medisch Centrum Utrecht | Utrecht | Netherlands | Completed |
| Studieenheten Akademiskt specialistcentrum | Stockholm | Sweden | Withdrawn |
This page is information, not medical advice. Discuss any trial with your doctor.